{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T04:09:30Z","timestamp":1776744570219,"version":"3.51.2"},"reference-count":17,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,5,23]]},"DOI":"10.7759\/cureus.15193","type":"journal-article","created":{"date-parts":[[2021,5,23]],"date-time":"2021-05-23T14:45:13Z","timestamp":1621781113000},"source":"Crossref","is-referenced-by-count":1,"title":["Pancytopenia Resulting From Low-Dose Methotrexate Use: A Diagnostic Challenge"],"prefix":"10.7759","author":[{"given":"Syed Wajih Ul","family":"Hassan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.4103\/0256-4947.51774","article-title":"Extra-articular manifestations of rheumatoid arthritis: a hospital-based study","volume":"29","author":"Al-Ghamdi A","year":"2009","unstructured":"Al-Ghamdi A, Attar SM. Extra-articular manifestations of rheumatoid arthritis: a hospital-based study. Ann Saudi Med. 2009, 29:189-93. 10.4103\/0256-4947.51774","journal-title":"Ann Saudi Med"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1097\/BOR.0b013e32835f693f","article-title":"Extra-articular rheumatoid arthritis","volume":"25","author":"Turesson C","year":"2013","unstructured":"Turesson C. Extra-articular rheumatoid arthritis. Curr Opin Rheumatol. 2013, 25:360-6. 10.1097\/BOR.0b013e32835f693f","journal-title":"Curr Opin Rheumatol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2015-0164","article-title":"Preventing and managing toxicities of high-dose methotrexate","volume":"21","author":"Howard SC","year":"2016","unstructured":"Howard SC, McCormick J, Pui CH, Buddington RK, Harvey RD. Preventing and managing toxicities of high-dose methotrexate. Oncologist. 2016, 21:1471-82. 10.1634\/theoncologist.2015-0164","journal-title":"Oncologist"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016\/s0885-3924(03)00312-9","article-title":"Pain during bone marrow aspiration: prevalence and prevention","volume":"26","author":"Vanhelleputte P","year":"2003","unstructured":"Vanhelleputte P, Nijs K, Delforge M, Evers G, Vanderschueren S. Pain during bone marrow aspiration: prevalence and prevention. J Pain Symptom Manage. 2003, 26:860-6. 10.1016\/s0885-3924(03)00312-9","journal-title":"J Pain Symptom Manage"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.2174\/1573397112666160824151801","article-title":"Low-dose methotrexate (LD-MTX) in rheumatology practice - a most widely misunderstood drug","volume":"12","author":"Malaviya AN","year":"2016","unstructured":"Malaviya AN. Low-dose methotrexate (LD-MTX) in rheumatology practice - a most widely misunderstood drug. Curr Rheumatol Rev. 2016, 12:168-76. 10.2174\/1573397112666160824151801","journal-title":"Curr Rheumatol Rev"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2014.08.027","article-title":"Clinical characteristics and risk factors for low dose methotrexate toxicity: a cohort of 28 patients","volume":"13","author":"Kivity S","year":"2014","unstructured":"Kivity S, Zafrir Y, Loebstein R, Pauzner R, Mouallem M, Mayan H. Clinical characteristics and risk factors for low dose methotrexate toxicity: a cohort of 28 patients. Autoimmun Rev. 2014, 13:1109-13. 10.1016\/j.autrev.2014.08.027","journal-title":"Autoimmun Rev"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/ket355","article-title":"Therapeutic drug monitoring in rheumatic  diseases: utile or futile?","volume":"53","author":"Stamp LK","year":"2014","unstructured":"Stamp LK, Barclay M. Therapeutic drug monitoring in rheumatic  diseases: utile or futile?. Rheumatology (Oxford). 2014, 53:988-97. 10.1093\/rheumatology\/ket355","journal-title":"Rheumatology (Oxford)"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1111\/1756-185X.13004","article-title":"Methotrexate-induced pancytopenia: a case series of 46 patients","volume":"20","author":"Ajmani S","year":"2017","unstructured":"Ajmani S, Preet Singh Y, Prasad S, et al.. Methotrexate-induced pancytopenia: a case series of 46 patients. Int J Rheum Dis. 2017, 20:846-51. 10.1111\/1756-185X.13004","journal-title":"Int J Rheum Dis"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1080\/03009740802360632","article-title":"Combination treatment with leflunomide and methotrexate for patients with active rheumatoid arthritis","volume":"38","author":"Lee SS","year":"2009","unstructured":"Lee SS, Park YW, Park JJ, et al.. Combination treatment with leflunomide and methotrexate for patients with active rheumatoid arthritis. Scand J Rheumatol. 2009, 38:11-4. 10.1080\/03009740802360632","journal-title":"Scand J Rheumatol"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.120922","article-title":"The SMILE study -- safety of methotrexate in combination with leflunomide in rheumatoid arthritis","volume":"40","author":"Bird P","year":"2013","unstructured":"Bird P, Griffiths H, Tymms K, et al.. The SMILE study -- safety of methotrexate in combination with leflunomide in rheumatoid arthritis. J Rheumatol. 2013, 40:228-35. 10.3899\/jrheum.120922","journal-title":"J Rheumatol"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1002\/pds.1236","article-title":"The incidence of pancytopenia in patients taking leflunomide alone or with methotrexate","volume":"16","author":"McEwen J","year":"2007","unstructured":"McEwen J, Purcell PM, Hill RL, Calcino LJ, Riley CG. The incidence of pancytopenia in patients taking leflunomide alone or with methotrexate. Pharmacoepidemiol Drug Saf. 2007, 16:65-73. 10.1002\/pds.1236","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1002\/pds.4555","article-title":"Concomitant use of low-dose methotrexate and NSAIDs and the risk of serious adverse events among patients with rheumatoid arthritis","volume":"27","author":"Svanstr\u00f6m H","year":"2018","unstructured":"Svanstr\u00f6m H, Lund M, Melbye M, Pasternak B. Concomitant use of low-dose methotrexate and NSAIDs and the risk of serious adverse events among patients with rheumatoid arthritis. Pharmacoepidemiol Drug Saf. 2018, 27:885-93. 10.1002\/pds.4555","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1053\/j.ajkd.2014.04.027","article-title":"Biopsy-proven acute interstitial nephritis, 1993-2011: a\u00a0case\u00a0series","volume":"64","author":"Muriithi AK","year":"2014","unstructured":"Muriithi AK, Leung N, Valeri AM, Cornell LD, Sethi S, Fidler ME, Nasr SH. Biopsy-proven acute interstitial nephritis, 1993-2011: a\u00a0case\u00a0series. Am J Kidney Dis. 2014, 64:558-66. 10.1053\/j.ajkd.2014.04.027","journal-title":"Am J Kidney Dis"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD000951.pub2","article-title":"Folic acid and folinic acid for reducing side effects in patients receiving methotrexate for rheumatoid arthritis","volume":"5","author":"Shea B","year":"2013","unstructured":"Shea B, Swinden MV, Tanjong Ghogomu E, et al.. Folic acid and folinic acid for reducing side effects in patients receiving methotrexate for rheumatoid arthritis. Cochrane Database Syst Rev. 2013, 5:CD000951. 10.1002\/14651858.CD000951.pub2","journal-title":"Cochrane Database Syst Rev"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-200262001-00005","article-title":"Filgrastim in patients with neutropenia: potential effects on quality of life","volume":"62 Suppl 1","author":"Lyman GH","year":"2002","unstructured":"Lyman GH, Kuderer NM. Filgrastim in patients with neutropenia: potential effects on quality of life. Drugs. 2002, 62 Suppl 1:65-78. 10.2165\/00003495-200262001-00005","journal-title":"Drugs"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-018-4242-8","article-title":"How should we manage low-dose methotrexate-induced pancytopenia in patients with rheumatoid arthritis?","volume":"37","author":"Cansu D\u00dc","year":"2018","unstructured":"Cansu D\u00dc, Teke H\u00dc, Bodak\u00e7i E, Korkmaz C. How should we manage low-dose methotrexate-induced pancytopenia in patients with rheumatoid arthritis?. Clin Rheumatol. 2018, 37:3419-25. 10.1007\/s10067-018-4242-8","journal-title":"Clin Rheumatol"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkl196","article-title":"Pharmacokinetic interaction between methotrexate and piperacillin\/tazobactam resulting in prolonged toxic concentrations of methotrexate","volume":"58","author":"Zarychanski R","year":"2006","unstructured":"Zarychanski R, Wlodarczyk K, Ariano R, Bow E. Pharmacokinetic interaction between methotrexate and piperacillin\/tazobactam resulting in prolonged toxic concentrations of methotrexate. J Antimicrob Chemother. 2006, 58:228-30. 10.1093\/jac\/dkl196","journal-title":"J Antimicrob Chemother"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/58209-pancytopenia-resulting-from-low-dose-methotrexate-use-a-diagnostic-challenge","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T19:33:30Z","timestamp":1707507210000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/58209-pancytopenia-resulting-from-low-dose-methotrexate-use-a-diagnostic-challenge"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5,23]]},"references-count":17,"URL":"https:\/\/doi.org\/10.7759\/cureus.15193","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2021,5,23]]}}}